Clinical Trials on Advanced Head and Neck Squamous Cell Carcinoma

Total 18081 results

Emory University
Astex Pharmaceuticals, Inc.

Recruiting

Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer

Head and Neck Carcinoma of Unknown Primary | Locally Advanced Head and Neck Squamous Cell Carcinoma | Locally Advanced Hypopharyngeal Squamous Cell Carcinoma | Locally Advanced Laryngeal Squamous Cell Carcinoma | Locally Advanced Nasopharyngeal Squamous Cell Carcinoma | Locally Advanced Oropharyngeal...

United States
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Comparing High-Dose Cisplatin Every Three Weeks to Low-Dose Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer

Advanced Head and Neck Squamous Cell Carcinoma | Squamous Cell Carcinoma of Unknown Primary | Advanced Hypopharyngeal Squamous Cell Carcinoma | Advanced Laryngeal Squamous Cell Carcinoma | Advanced Oropharyngeal Squamous Cell Carcinoma

United States, Canada
Xuekui Liu

Not yet recruiting

Cetuximab+Zimberelimab in Combination With Cisplatin and Nab-paclitaxel in Resctable Head and Neck Squamous Cell Carcinoma (CZCNRHNSCC)

Hend and Neck Squamous Cell Carcinoma Locally Advanced Operable

China
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Recruiting

Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition

Recurrent Head and Neck Squamous Cell Carcinoma | Advanced Head and Neck Squamous Cell Carcinoma | Metastatic Head-and-neck Squamous-cell Carcinoma | Locally Advanced Head and Neck Squamous Cell Carcinoma | Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck | Stage IV Cutaneous...

United States
British Columbia Cancer Agency

Withdrawn

Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)

Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)

Canada
Glenn J. Hanna
Secura Bio, Inc.

Active, not recruiting

Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC

Metastatic Head and Neck Cancer | Advanced Head and Neck Squamous Cell Carcinoma | Recurrent Squamous Cell Carcinoma of the Head and Neck | Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Advanced Head and Neck Cancer

United States
Biotech Pharmaceutical Co., Ltd.

Completed

A Real-world Study of the Efficacy and Safety of Nimotuzumab in Combination With Chemoradiotherapy for LASCCHN (Redbull-1)

Locally Advanced Head and Neck Squamous Cell Carcinoma

China
Seoul National University Hospital
Clinical Research Center for Solid Tumor, Korea

Completed

Efficacy Study of Genexol-PM and Cisplatin in Locally Advanced Head and Neck Cancer

Locally Advanced Head and Neck Squamous Cell Carcinoma

Korea, Republic of
AstraZeneca

Recruiting

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC)

Locally Advanced Head and Neck Squamous Cell Carcinoma

Spain, United States, Italy, Korea, Republic of, United Kingdom, Vietnam, France, Japan, Brazil, India, Thailand, Germany, Canada, Turkey, Malaysia, Taiwan, Belgium, Austria, Hungary
Tianjin Medical University General Hospital
Tianjin Medical University Cancer Institute and Hospital

Not yet recruiting

Neoadjuvant Radiotherapy Combined With Toripalimab for Locally Advanced Head and Neck Squamous Cell Carcinoma

Locally Advanced Head and Neck Squamous Cell Carcinoma

China
Nanfang Hospital, Southern Medical University

Not yet recruiting

Toripalimab Maintenance for Locally Advanced Head and Neck Squamous Cell Carcinoma

Locally Advanced Head and Neck Squamous Cell Carcinoma
European Organisation for Research and Treatment...
Merck KGaA, Darmstadt, Germany

Recruiting

Radiotherapy Plus Xevinapant in Older Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (RAVINA)

Locally Advanced Head and Neck Squamous Cell Carcinoma

France, Belgium, Netherlands, Norway, United Kingdom, Ireland, Italy, Slovenia, Germany, Spain
Canadian Cancer Trials Group
NuBiyota

Withdrawn

PembROlizumab With or Without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma (PROMOTE-HN)

Advanced Head and Neck Squamous Cell Carcinoma
Krzysztof Misiukiewicz
Regeneron Pharmaceuticals

Recruiting

Study of Cemiplimab - TP Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Locally Advanced Head and Neck Squamous Cell Carcinoma

United States
Guiyang Medical University

Unknown

Docetaxel and Loplatin Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced SCCHN

Locally Advanced Head and Neck Squamous Cell Carcinoma

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

A Prospective Randomized Controlled Study of Immune Checkpoint Maintenance Therapy After Radiotherapy and Chemotherapy for Locally Advanced Head and Neck Tumors Based on Peripheral Blood CD8Tex Detection in Peripheral Blood

Locally Advanced Head and Neck Squamous Cell Carcinoma

China
Ohio State University Comprehensive Cancer Center

Active, not recruiting

Group-Mediated Cognitive Behavioral Resistance Exercise Intervention in Head and Neck Cancer Patients Undergoing Chemoradiation Treatment

Locally Advanced Head and Neck Squamous Cell Carcinoma

United States
Rakuten Medical, Inc.

Active, not recruiting

An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head-and-neck Squamous-cell Carcinoma | Metastatic Cutaneous Squamous Cell Carcinoma | Locally Advanced Cutaneous Squamous Cell Carcinoma

United States
Kantonsspital Winterthur KSW
UMC Utrecht; University of Lausanne; Zurich University of Applied Sciences; University... and other collaborators

Not yet recruiting

Influencing Factors for Physical Activity in People With Head and Neck Cancer (ProAct-HNC)

Advanced Head and Neck Squamous Cell Carcinoma
Hospital Universitario Doctor Peset

Recruiting

Induction Modified TPF Followed by Concurrent Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Locally Advanced Head and Neck Squamous Cell Carcinoma

Spain
University of Erlangen-Nürnberg Medical School

Completed

Radiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCC

Locally Advanced Head and Neck Squamous Cell Carcinoma

Germany
Fifth Affiliated Hospital, Sun Yat-Sen University

Recruiting

Toripalimab Combined With Gemcitabine and Cisplatin Treating Resectable Locally Advanced HNSCC

Neoadjuvant Therapy | Locally Advanced Head and Neck Squamous Cell Carcinoma

China
Lawson Health Research Institute

Recruiting

Low-Dose Weekly vs High-Dose Cisplatin (RADIO)

Locally Advanced Head and Neck Squamous Cell Carcinoma

Canada
Nanobiotix

Recruiting

NBTXR3 With or Without Cetuximab in LA-HNSCC

Aged | Locally Advanced Head and Neck Squamous Cell Carcinoma

France, Spain, Israel, United States, Taiwan, Finland, Japan, Belgium, Korea, Republic of, Hungary, China, Georgia, Portugal, Austria, Bulgaria, Canada, Czechia, Germany, Greece, Romania, Serbia
University Health Network, Toronto
AstraZeneca; NeoGenomics Laboratories

Recruiting

Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC (MERIDIAN)

Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)

Canada
Celldex Therapeutics

Terminated

A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Advanced Head and Neck Squamous Cell Carcinoma

United States
China Medical University Hospital

Completed

Biweekly TPF Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of Head and Neck

Locally Advanced Head and Neck Carcinoma
Xiang Lu

Recruiting

Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinomas | Resectable Head and Neck Squamous-cell Carcinoma

China
University Hospital, Antwerp
Agentschap voor Innovatie door Wetenschap en Technologie

Completed

Combined FDG PET/CT Imaging in Response Evaluation After Radiochemotherapy in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) (ECLYPS)

Locally Advanced Squamous Cell Carcinoma of the Head and Neck Region

Belgium, Netherlands
Incyte Biosciences International Sàrl

Withdrawn

INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Recurrent Head and Neck Squamous Cell Carcinoma | Advanced Malignancies | Metastatic Head and Neck Squamous Cell Carcinoma

United States
Xuekui Liu

Recruiting

Neoadjuvant Cadonilimab in Combination With Cisplatin and Nab-paclitaxel in Resectable Head and Neck Squamous Cell Carcinoma (NCCCNRHNSCC)

Head and Neck Squamous Cell Carcinoma | Locally Advanced Operable

China
Barretos Cancer Hospital

Recruiting

Induction Chemotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma (INDUCTION)

Locally Advanced Malignant Neoplasm

Brazil
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Head and Neck Squamous Cell Carcinoma (REDUCTION-I)

Head and Neck Squamous Cell Carcinomas

China
Hoffmann-La Roche

Terminated

A Study of Atezolizumab (Anti-Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)

United States, Korea, Republic of, Canada, Australia, Russian Federation, United Kingdom, Belgium, Brazil, China, France, Italy, Portugal, Spain, Japan, India, Thailand, Ukraine, Taiwan, Poland, Turkey, Hungary, South Africa, Germany
Arnaud Bewley, MD
National Cancer Institute (NCI); Genentech, Inc.

Terminated

Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary Site

Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 | Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck | Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck

United States
Lai-ping Zhong
Sun Yat-sen University; Fudan University; Fujian Medical University; Central South...

Recruiting

Neoadjuvant Immunochemotherapy for LAOSCC

Oral Squamous Cell Carcinoma | Locally Advanced Head and Neck Carcinoma

China
Xiangya Hospital of Central South University
Hunan Cancer Hospital; The Second Affiliated Hospital of University of South...

Recruiting

TPExtreme Induced Chemotherapy Followed by Surgery and Radiotherapy in the Oral Carcinoma.

Oral Squamous Cell Carcinoma | Locally Advanced Head and Neck Squamous Cell Carcinoma

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

A Study of Toripalimab as Consolidation Therapy After Postoperative Chemoradiotherapy in HNSCC

Head and Neck Squamous Cell Carcinomas

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)

Head and Neck Squamous Cell Carcinomas

China
Ascendis Pharma Oncology Division A/S

Recruiting

A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors

Advanced Solid Tumor | Metastatic Solid Tumor | Locally Advanced Solid Tumor | Neoadjuvant Melanoma | Head and Neck Squamous Cell Carcinoma HNSCC | HPV-associated Cancers | Neoadjuvant Cutaneous Squamous Cell Carcinoma (cSCC)

United States, Australia, Spain, Netherlands, Korea, Republic of, Taiwan
AstraZeneca
MedImmune LLC

Active, not recruiting

Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck

Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck

Spain, United States, Belgium, Germany, United Kingdom, Italy
Merck KGaA, Darmstadt, Germany
Merck Ltd., India

Terminated

A Post Marketing Surveillance Study to Assess the Safety and Efficacy of Cetuximab Plus Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck (PMS LAD SCCHN)

Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck | LA SCCHN

India
Replimune Inc.
Bristol-Myers Squibb

Withdrawn

Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN

Squamous Cell Carcinoma of Head and Neck | Recurrent Head and Neck Squamous Cell Carcinoma | Locally Advanced Head and Neck Squamous Cell Carcinoma

United States, Spain, United Kingdom, Czechia, France, Germany, Greece, Poland
Hi-Q Marine Biotech International, Ltd.

Recruiting

A Randomized, Double-blind Study to Evaluate the Clinical Effect and Safety of Fucoidan in Patients With Squamous Cell Carcinomas of the Head and Neck

Squamous Cell Carcinomas of the Head and Neck

Taiwan
Coherus Biosciences, Inc.

Recruiting

Study of CHS-114 in Participants With Advanced Solid Tumors

Advanced Solid Tumor | Head and Neck Squamous Cell Carcinoma

United States
Bayer
Merck Sharp & Dohme LLC

Active, not recruiting

Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1.

Advanced Solid Tumor | Head and Neck Squamous Cell Carcinoma

United States
Incyte Corporation

Active, not recruiting

Study of INCA 0186 in Subjects With Advanced Solid Tumors

Advanced Solid Tumors | Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Gastrointestinal (GI) Malignancies

United States, Netherlands, Spain, United Kingdom, Belgium, Austria
AbbVie
Idera Pharmaceuticals, Inc.

Completed

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Advanced Solid Tumors Cancer

United States, France, Germany, Israel, Netherlands, Spain
Assistance Publique - Hôpitaux de Paris
National Cancer Institute (NCI); Canceropôle Ile de France

Completed

Comprehensive Geriatric Assessment and Head and Neck Elderly Cancer Patients (EGéSOR)

Head and Neck Squamous Cell Carcinomas (HNSCCs)

France
University Health Network, Toronto

Completed

Role of Microbiome as a Biomarkers in Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma (ROMA LA-OPSCC)

Locoregionally-advanced Oropharyngeal Squamous Cell Carcinoma

Canada

Clinical Trials on Advanced Head and Neck Squamous Cell Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations